ACTINIUM PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$998.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2023-05-15
- ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-12-31 was -$91.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-09-30 was -$113.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-06-30 was -$63.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-03-31 was -$731.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$998.00K, a 200.00% decline from fiscal 2021.
- ACTINIUM PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $998.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$204.00K derived: sum of 2 quarters · filed 2023-03-31 | -$267.00K derived: sum of 3 quarters · filed 2023-03-31 | -$998.00K 10-K · filed 2023-03-31 |
| 2022-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$176.00K derived: sum of 2 quarters · filed 2022-11-14 | -$907.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$794.00K 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | -$731.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $998.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |